Description:
This 2-day seminar includes an overview of Adaptive Design, and an emphasis in group sequential design, sample size re-estimation, and Phase II/III Adaptive Seamless Designs.
The role of statistics in clinical trials incorporates the tools used to develop a robust study, minimize bias, and assess efficacy of new treatments as relates to comparison to competing therapies.
Randomized clinical trials remain the standard for clinical research. However, the cost of a traditional randomized controlled trial especially in large sample sizes and long study duration, are limiting factors of innovation in the pharmaceutical and medical device arenas. A trial with an adaptive design can often result in lower costs and more efficiency by making use of interim analyses with data accumulated during the course of a trial to modify a study, without compromising validity and integrity. Adaptive designs also allow for checking trial assumptions and progress before the conclusion of the study. Studies can be adapted for dose response, patient accrual, and early stopping for futility or patient safety concerns.
However, there are special considerations in the planning and execution of a adaptive design to control Type I error rates and ensure consistency of treatment. In additional to protocol considerations, the FDA and regulatory agencies also require particular assurances that an adaptive design will incorporate flexibility at the expense of sacrificing study validity and patient safety.
The objective of the seminar is to provide information that can be used immediately by personnel involved in the design and analysis of clinical trials. The presentation involves use of statistical techniques and a basic understanding of statistical theory and the framework of randomized controlled trials is desired. However, presentation of statistical theory and application will be limited to only what is needed by the attendees to understand and implement adaptive trial design and analysis.
R statistical software will be used to demonstrate analyses and simulation studies within the adaptive design framework. So bring your laptop computer!
Why should you attend:
Clinical trials are expensive, time consuming, and labor-intensive. And in the traditional sense, study designs are inflexible.
Adaptive study designs allow for flexibility during a clinical trial. Options can be built into a study to use data collected that has accumulated at interim time points to:
Adjust sample sizes in treatment arms or reduce patient recruitment.
Drop treatment arms entirely (treatment pruning)
Adjust randomization schema
Combine Phase II and Phase III (adaptive seamless design)
Early stopping of a study for futility or success.
The U.S. Food and Drug Administration (FDA) and other regulatory agencies require the minimization of bias in study design and analysis. In order to minimize bias, particular steps and safeguards, using regulatory guidance and sound statistical principles, must be put into place to assure validity of an clinical.
Therefore a number of considerations must be made in the design of an adaptive trial to enhance flexibility while minimizing bias, and ensuring statistically valid and well-informed decisions. Problems can arise in an adaptive design due to selection bias, interim analysis "look-sies", and when merging dose selection and confirmation phases into one trial.
The benefits of a clinical trial with an adaptive design include savings in both time and dollars, to the desired end of bringing useful drug treatments and devices to patients more quickly.
Areas Covered in the Session:
Overview of Applications for Adaptive Design in Clinical Trials
Statistical Techniques of Adaptive Design
Practical Considerations for implementation of an Adaptive Design
Regulatory Aspects of an Adaptive Design
When an Adaptive Design is, and is not, Appropriate
Examples of Clinical Trials that Incorporated Adaptive Design
Computer Code in R Statistical Software for Simulation Studies
Who will benefit:
Trial Sponsors
Principal Investigators
Clinical Investigators
Clinical Research Statisticians
Clinical Research Coordinators
Clinical Research Nurse Coordinators
Clinical Research Associates/Assistants
Clinical Project Managers/Leaders
Study Managers
Regulatory Professionals/Coordinators
Medical Writers who need to interpret statistical reports
Agenda:
Day 1 Schedule
Lecture 1 (90 Mins):
Introduction
The What, Why, and When of Adaptive Design
Logic and Terminology of Adaptive Design
Rules of Allocation, Sampling, Stopping, Decisions
Flexible aspects of Adaptive design
Overview of Types of Adaptive Designs
Investigate phases
Confirmatory phases
Lecture 2 (90 Mins):
Group Sequential Design
Interim Analysis considerations
Prematurely stopping a trial due to:
Safety concerns
efficacy or futility
Lecture 3 (90 Mins):
Statistical Methods for Group Sequential Designs
Maximum information and information fractions
Pocock and O’Brien Fleming boundaries
Alpha spending
Covariate Adjustments
Enrichment Design
Lecture 4 (90 Mins):
Sample Size Re-Estimation (SSR)
Why would we want to re-assess the sample size?
Uncertainty in Assumptions and/or available information
Underpowered Study
Protecting the Study Blind
Statistical Considerations of SSR
Adaptation Rules: Effect Size Ratio
Adaptation Rules: Conditional Power
Adjustment of point estimates, confidence intervals, p-value
Day 2 Schedule
Lecture 1 (90 Mins):
Phase II/III Adaptive Seamless Designs: Overview and Applications
Why an Adaptive Seamless Design?
Terms and Reasoning
Dose Selection
Treatment Pruning
When and When Not to Use Adaptive Seamless Design
Special Considerations for Adaptive Seamless Design
Lecture 2 (90 Mins):
Phase II/III Adaptive Seamless Designs: Statistical Methods
Closed Testing Approach
Simes procedure to control multiplicity
Inverse Normal Method
Simulation Testing for Power Comparison
Lecture 3 (90 Mins):
Practical Procedural and Regulatory Issues of Adaptive Design
Concerns of Validity, Bias, Robustness of the Study
Planning for an Adaptive Study
Working with Regulatory Agencies
Concerns and Controls for Repeated Testing (Multiplicity)
Monitoring and Decision Making in an Adaptive Study
Lecture 4 (90 Mins):
Case Study and Protocol Examples, Q&A/Discussion
An open review and discussion of adaptive trials in which researchers incorporated the four adaptive design rules.
Examples of protocol and statistical analysis plan sections using an adaptive trial framework
Question and Answer Session
Speaker:
Elaine Eisenbeisz
Owner and Principal Statistician, Omega Statistics
Elaine Eisenbeisz, is a private practice statistician and owner of Omega Statistics, a statistical consulting firm based in Southern California. Elaine has over 30 years of experience in creating data and information solutions for industries ranging from governmental agencies and corporations, to start-up companies and individual researchers.
Location: Philadelphia, PA Date: November 15th & 16th, 2018 and Time: 9:00 AM to 6:00 PM
Venue: DoubleTree by Hilton Philadelphia Airport 4509 Island Avenue, Philadelphia, PA 19153
Price:
Until October 10, Early Bird Price: $1,295.00 Price: $1,295.00 (Seminar Fee for One Delegate)
From October 11 to November 13, Regular Price: $1,495.00
Register for 5 attendees Price: $3,885.00 $6,475.00 You Save: $2,590.00 (40%)*
Register for 10 attendees Price: $7,122.00 $12,950.00 You Save: $5,828.00 (45%)*
Register now and save $200. (Early Bird)
Sponsorship Program benefits for seminar
For More Information- https://www.globalcompliancepanel.com/control/sponsorship
Contact us today!
NetZealous LLC DBA GlobalCompliancePanel
john.robinson@globalcompliancepanel.com
Toll free: +1-800-447-9407
Phone: +1-510-584-9661
Website: http://www.globalcompliancepanel.com
Registration Link - https://www.globalcompliancepanel.com/control/globalseminars/~product_id=901894SEMINAR?seo
Follow us on LinkedIn: https://www.linkedin.com/company/globalcompliancepanel/
Like us our Facebook page: https://www.facebook.com/TrainingsAtGlobalCompliancePanel/
Follow us on Twitter: https://twitter.com/GCPanel